Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

04. Februar 2026 16:01 ET | Quelle: Ascendis Pharma

Ascendis Pharma to Report Full Year 2025 Financial Results and Provide Business Update on February 11, 2026

COPENHAGEN, Denmark, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it plans to report full year 2025 financial results and provide a business update on...
09. Januar 2026 18:01 ET | Quelle: Ascendis Pharma

Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference

COPENHAGEN, Denmark, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today provided a business and strategic roadmap update, including planned 2026 key corporate milestones....
08. Januar 2026 16:01 ET | Quelle: Ascendis Pharma

Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH)

– Once-weekly TransCon® CNP and TransCon® hGH combination therapy showed durable growth without compromising safety or tolerability at 52 weeks – Annualized growth velocity (AGV) exceeded the...
05. Januar 2026 08:30 ET | Quelle: Ascendis Pharma

Ascendis Pharma to Participate in the 44th Annual J.P. Morgan Healthcare Conference

COPENHAGEN, Denmark, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in the 44th Annual J.P. Morgan Healthcare...